Researchers combined data from multiple studies to look at gamma neuromodulation, a type of brain stimulation, for people with neuropsychiatric disorders. The review included patients with schizophrenia, major depressive disorder, bipolar disorder, and autism spectrum disorder, totaling over 2,000 participants across the included studies. The main goal was to see if this treatment helped reduce symptoms and improve thinking skills.
The analysis showed promising results for patients with schizophrenia. Those receiving gamma neuromodulation experienced improvements in positive symptoms, negative symptoms, depressive feelings, anxiety, and overall cognitive function compared to other groups. For people with major depressive disorder, the treatment was linked to a reduction in depressive symptoms. The statistical evidence for these benefits was generally strong.
No safety concerns were reported in the review, as data on adverse events were not provided by the included studies. The main reason to be cautious is that the studies varied greatly in how the treatment was delivered, which makes it difficult to know exactly what works best. Readers should understand that while the results are encouraging, more consistent and larger trials are needed to confirm these findings and guide standard medical practice.